FAT1 and colorectal carcinoma: Our data not only point to the effectiveness of antibody-mediated immunotherapies targeting more than one tumor-specific B cell antigen/epitope but also suggest that the combination of D8-FAT1 and EGFRvIII might find practical applications in CRC patients since EGFRvIII expression has been described in at least a subset of human colorectal cancers (33).